<DOC>
	<DOC>NCT02991612</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.</brief_summary>
	<brief_title>Rifaximin in Patients With Gastroesophageal Variceal Bleeding</brief_title>
	<detailed_description>Gastroesophageal variceal bleeding is the most common and life-threatening condition in patients with portal hypertension, which are susceptibility to bacterial infection. However, the prophylaxis use of antibiotics remained uncertain and lack of high level evidences.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Esophageal and Gastric Varices</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>18 y.o. ≤age≤75 y.o.; Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric N butylcyanoacrylate injection). age &lt;18 y.o. or age &gt; 75 y.o.; Never had the variceal bleeding episode before; Do not have endoscopic treatment; combined with other malignant tumor (not exclude patients with hepatocellular carcinoma who don't not need treatment at the moment); Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.) Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics. Acute variceal bleeding within 5 days. Use of other antibiotics in the past 2 weeks; Refuse to participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>